Moderna

An animal study that was published in the journal Cell on Wednesday shows that an experimental Moderna mRNA vaccine for mpox has proven to be more effective than existing vaccinations in lowering the symptoms and duration...

Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025. Shares...

Moderna Inc said on Friday it was planning to hire about 2,000 employees globally by 2023-end and set up new offices on the U.S. West Coast, as it aims to scale up development of new products...

Moderna Inc has refused to hand over to China the core intellectual property behind the development of its COVID-19 vaccine, leading to a collapse in negotiations on its sale there, the Financial Times reported on Saturday,...

The US Centers for Disease Control and Prevention (CDC) on Thursday recommended Covid-19 booster shots from Pfizer and Moderna targeting the Omicron variant, clearing the way for the administration of the shots. This new generation of...

Scientists in South Africa have made a copy of the Moderna Covid vaccine, a move which they say could help boost vaccination rates across Africa. The continent currently has the lowest uptake of Covid shots in...

Moderna’s Covid-19 “Spikevax” vaccine, which had previously acquired an emergency use license in the United States, has now received full approval from the US Food and Drug Administration (FDA). “The public can be assured that Spikevax...

Moderna announced Monday that it plans to release a combined Covid-flu-RSV booster vaccine in late 2023, in the hopes that a combined vaccination will motivate consumers to obtain an annual injection. Before 2024, a single vaccination...

Moderna, a US pharmaceutical company, announced on Friday that it will create a booster shot to combat the new Omicron coronavirus type. Moderna said it is one of three tactics the business is pursuing to combat...

Moderna’s Covid-19 vaccine might become the second teenage vaccine licensed in the European Union (EU) after regulators recommended approval for 12 to 17-year-olds on Friday, ahead of US officials. The vaccine, Spikevax, will be used the...